Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation

NCT07729332 · Not yet recruiting

Last updated 2026-08-27

This clinical trial is testing whether switching to oral weight management medications can help prevent weight regain in adults with obesity after they stop taking GLP-1 therapy.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 60 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2026-11 · est. completion 2031-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07729332 ↗

Description as written by the study sponsor.

This study will compare the effect of orforglipron and phentermine on weight maintenance.

Treatments tested

Phentermine Pill Drug

Phentermine 8 mg or 37.5 mg tablet
Orforglipron Drug

orforglipron 0.8, 2.5, 5.5, 9, 14.5 or 17.2 mg tablets

Main thing measured	Percent change in body weight
Sponsor	Massachusetts General Hospital
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07729332 ↗